TEVA files Form 144 to sell 447,778 shares

TEVA Pharmaceuticals filed a Form 144 reporting the planned sale of 447,778 ordinary shares.

Accepted by SEC EDGAR 02/18/2026 - 06:12 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

TEVA Pharmaceuticals filed a Form 144 reporting the planned sale of 447,778 ordinary shares. The filing lists Citigroup Global Markets Inc. as the broker and shows the transaction date 02/17/2026 on the NYSE. The filing also lists restricted share unit and performance share unit award amounts of 161,656 and 620,110 respectively, both with an award date of 02/15/2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 report?

The Form 144 reports a planned sale of 447,778 ordinary shares through Citigroup Global Markets Inc. with a listed transaction date of 02/17/2026. The filing identifies the exchange as NYSE and includes award details for equity grants.

Which broker is handling the TEVA share sale?

The filing names Citigroup Global Markets Inc. as the broker for the transaction. The document pairs the broker with the listed sale amount of 447,778 ordinary shares and the execution venue noted as NYSE on 02/17/2026.

Does the Form 144 list any equity awards for TEVA?

Yes. The filing lists a restricted share unit award of 161,656 and a performance share unit award of 620,110, both showing an award date of 02/15/2023 and included in the filing’s securities information.

On which exchange is the TEVA sale planned?

The filing indicates the sale is planned on the NYSE, with the transaction date shown as 02/17/2026. The document pairs the exchange designation with the broker and the listed share amount of 447,778 ordinary shares.

Is the Form 144 transaction size material to TEVA’s capital structure?

The filing lists 447,778 ordinary shares for sale but does not include additional context on outstanding shares or dilution within the excerpt. The document also lists award amounts of 161,656 RSUs and 620,110 PSUs dated 02/15/2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001673277
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Francis Richard D
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	PRESIDENT AND CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	447778	447778.00	15324798	02/17/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	02/15/2023	RESTRICTED SHARE UNIT AWARD	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			161656	02/17/2026	COMPENSATION
ORDINARY SHARES	02/15/2023	PERFORMANCE SHARE UNIT AWARD	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			620110	02/17/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SECTION 3E SHARES OR OTHER UNITS OUTSTANDING BASED ON ORDINARY SHARES. SHARES WERE SOLD PURSUANT TO A 10B51 PLAN ESTABLISHED IN NOV 2025. SHARES WERE SOLD FROM RESTRICTED SHARE UNIT AWARD AND PERFORMANCE SHARE UNIT AWARD. SOME OF THE SHARES COVERED REQUIRED OBLIGATIONS
Date of Notice	02/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)